Deals Of The Week: Baxter/Gambro, Optimer/AstraZeneca, Ironwood/Protagonist
Three rapid-fire clinical setbacks scuttled a planned merger between BioCryst and Presidio that would have created a new competitor in the hepatitis C space. Now, BioCryst is retrenching with a staff cut and narrower R&D focus.
You may also be interested in...
Optimer has signed a string of partnerships to commercialize the antibiotic around the world; the latest is with AstraZeneca, which will market the drug in South America, Central America, Mexico and the Caribbean.
The latest public-private partnerships to be announced under the EU’s Innovative Medicines Initiative includes the StemBANCC project involving 10 pharmaceutical companies and 23 academic institutions working together to develop patient-derived induced stem cell lines for drug development.
Italian life sciences seed capital firm Eporgen Venture has used a network of wealthy individuals in Italy to fund a group of new biotech companies, and has entered into its first transaction, selling Genovax’s potential cancer vaccine to Italian pharmaceutical company Mediolanum.